remibrutinib

Small molecule

Also known as LOU064

Approvedregulatory verdict

Evidence outlook

Approved: Chronic Spontaneous Urticaria

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Multiple Sclerosis · Phase 3Hidradenitis Suppurativa · Phase 3Secondary Progressive Multiple Sclerosis · Phase 3

Also approved (5)
US
  • Symptomatic dermographism (SD) in adults inadequately controlled by H1 antihistamines (supplemental indication, NDA218436 S-1)
Product first approved 2025Outside this platform's coveragenovartis.com
CA
  • RHAPSIDO (remibrutinib tablets) is indicated for: • the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment.
Product first approved 2026Health Canada
EU
  • Rhapsido is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1 antihistamine treatment.
Product first approved 2026EMA
UK
  • Chronic spontaneous urticaria (CSU) in adults inadequately controlled by H1 antihistamines
novartis.com
CN
  • Chronic spontaneous urticaria (CSU) in adults inadequately controlled by H1 antihistamines
novartis.com

Development in Generalized Myasthenia Gravis stopped (2026-10-27) after a negative readout. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (22)
Chronic Spontaneous Urticaria
NCT07816328 · Novartis Pharmaceuticals
2026-09-21 – 2028-05-24 · Chronic Spontaneous Urticaria
What this study did
NCT05513001 · Novartis Pharmaceuticals
2022-12-09 – 2027-08-02 · Chronic Spontaneous Urticaria
What this study did
NCT06868212 · Novartis Pharmaceuticals
2025-07-11 – 2027-05-17 · Chronic Spontaneous Urticaria (CSU)
What this study did
NCT05048342 · Novartis Pharmaceuticals
2022-01-15 – 2023-12-09 · Chronic Spontaneous Urticaria
What this study did
Hidradenitis Suppurativa
NCT07665437 · Novartis Pharmaceuticals
2026-07-10 – 2031-10-15 · Hidradenitis Suppurativa
What this study did
NCT06840392 · Novartis Pharmaceuticals
2025-03-20 – 2027-10-21 · Hidradenitis Suppurativa
What this study did
NCT06799000 · Novartis Pharmaceuticals
2025-01-31 – 2027-10-04 · Hidradenitis Suppurativa
What this study did
Multiple Sclerosis
NCT06846281 · Novartis Pharmaceuticals
2025-06-23 – 2031-06-25 · Relapsing Multiple Sclerosis
What this study did
Secondary Progressive Multiple Sclerosis
NCT07225504 · Novartis Pharmaceuticals
2025-11-11 – 2034-01-02 · Secondary Progressive Multiple Sclerosis (SPMS)
What this study did
Other / comorbidity
NCT06744920 · Novartis Pharmaceuticals
2025-02-07 – 2033-02-26 · Generalized Myasthenia Gravis
What this study did
NCT07456891 · Novartis Pharmaceuticals
2026-04-16 – 2033-01-30 · Indication of the Parent Protocol
What this study did
NCT07700056 · Novartis Pharmaceuticals
2026-08-24 – 2030-04-15 · Chronic Pruritus of Unknown Origin
What this study did
NCT07811869 · Novartis Pharmaceuticals
2026-10-07 – 2030-01-03 · Chronic Pruritus of Unknown Origin
What this study did
NCT07768371 · Novartis Pharmaceuticals
2026-08-27 – 2029-12-31 · IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
What this study did
NCT05976243 · Novartis Pharmaceuticals
2023-12-07 – 2029-06-15 · Chronic Inducible Urticaria
What this study did
Phase 2 (9)
Chronic Spontaneous Urticaria
NCT06865651 · Novartis Pharmaceuticals
2025-05-22 – 2027-09-28 · Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
What this study did
NCT04109313 · Novartis Pharmaceuticals
2019-10-24 – 2022-09-09 · Chronic Spontaneous Urticaria
What this study did
NCT03926611 · Novartis Pharmaceuticals
2019-06-06 – 2021-04-15 · Chronic Spontaneous Urticaria
What this study did
Hidradenitis Suppurativa
NCT03827798 · Novartis Pharmaceuticals
2019-02-27 – 2026-09-11 · Hidradenitis Suppurativa
What this study did
Secondary Progressive Multiple Sclerosis
NCT07222956 · Moein Amin
2027-03-01 – 2030-12-30 · Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
What this study did
Other / comorbidity
NCT07681271 · Novartis Pharmaceuticals
2026-07-30 – 2027-12-07 · Papulopustular Rosacea
What this study did
NCT05432388 · Novartis Pharmaceuticals
2022-10-12 – 2025-03-11 · Allergy, Peanut
What this study did
NCT04035668 · Novartis Pharmaceuticals
2019-07-12 – 2021-11-23 · Sjögren Syndrome
What this study did
NCT03944707 · Novartis Pharmaceuticals
2019-07-18 – 2020-04-27 · Asthma
What this study did
Phase 1 (4)
Hidradenitis Suppurativa
NCT07855276 · Novartis Pharmaceuticals
2026-10-29 – 2027-12-27 · Hidradenitis Suppurativa
What this study did
Other / comorbidity
NCT07032272 · Novartis Pharmaceuticals
2025-07-23 – 2025-10-14 · Autoimmune and Chronic Inflammatory Diseases
What this study did
NCT05753592 · Novartis Pharmaceuticals
2022-10-31 – 2023-12-17 · Hepatic Impairment
What this study did
NCT03918980 · Novartis Pharmaceuticals
2016-08-18 – 2020-01-27 · Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Multiple Sclerosis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Remibrutinib: this drugPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
AlemtuzumabApprovedMonoclonal antibodyCD52Partial signal
NCT00930553: Annualized Relapse Rate (ARR) (Year 3, 4, 5, 6 from the Baseline (Month 0 of CAMMS323 and Month 0 of CAMMS324 for "Alemtuzumab Treatment CAMMS323 Extension" group and "Alemtuzumab Treatment CAMMS324 Extension" group, respectively)): Alemtuzumab Treatment CAMMS323 Extension — Year 3: 0.19 relapses per participant per year; Year 4: 0.16 relapses per participant per year; Year 5: 0.15 relapses per participant per year; Year 6: 0.12 relapses per participant per year | Alemtuzumab Treatment CAMMS324 Extension — Year 3: 0.22 relapses per participant per year; Year 4: 0.24 relapses per participant per year; Year 5: 0.19 relapses per participant per year; Year 6: 0.16 relapses per participant per year
NCT00548405: Percentage of Participants With Sustained Accumulation of Disability (SAD) (Up to 2 years): Alemtuzumab 12 mg 12.71% (95% CI 9.89 to 16.27) vs Interferon Beta-1a 21.13% (95% CI 15.95 to 27.68)
BafiertamApprovedSmall moleculeNrf2 pathway (fumaric acid ester)not yet gradedNo reviewed efficacy summary in this indication
Cladribine (MAVENCLAD®)ApprovedSmall moleculeAdenosine deaminase-resistant purine analog, DNA synthesis machinery in lymphocytesReliable signal
NCT00213135: Annualized Qualifying Relapse Rate (Week 96): Cladribine 5.25 mg/kg 0.15 relapses per year (95% CI 0.12 to 0.17) | Cladribine 3.5 mg/kg 0.14 relapses per year (95% CI 0.12 to 0.17) vs Placebo 0.33 relapses per year (95% CI 0.29 to 0.38)
CopaxoneApprovedPeptideMyelin basic protein-mimetic immunomodulationnot yet gradedNo reviewed efficacy summary in this indication
Dimethyl Fumarate (Tecfidera)ApprovedSmall moleculeNrf2 pathway (fumaric acid ester)Reliable signal
NCT00451451: Adjusted annualized relapse rate at 2 years: 0.224 relapses/year (95% CI 0.179–0.282) with BG00012 240 mg BID vs 0.401 (95% CI 0.329–0.488) with placebo; 0.198 (95% CI 0.156–0.252) with BG00012 240 mg TID vs 0.401 (95% CI 0.329–0.488) with placebo.
NCT00420212: Estimated proportion relapsed by 2 years: 27% with BG-12 240 mg twice daily and 26% with 240 mg three times daily vs 46% with placebo (P<0.001 for both comparisons) (DEFINE, N Engl J Med 2012).
Diroximel Fumarate (Vumerity)ApprovedSmall moleculeNrf2 pathway (fumaric acid ester)Weak signal
NCT03093324: Primary GI symptom days: mean 1.5 (SD 2.85) with ALKS 8700 vs 2.5 (SD 4.68) with dimethyl fumarate; rate ratio 0.542 (95% CI 0.390-0.754), p=0.0003.
Fampridine (Ampyra / Fampyra)ApprovedSmall moleculePotassium Channel Blocker, Voltage-gated potassium channel (Kv), Voltage-gated potassium channels (Kv1/Shaker/KCNA family)Partial signal
NCT00127530: Timed walk responders: fampridine 78/224 (35%) vs placebo 6/72 (8%), p<0.0001 (Goodman et al., Lancet 2009)
Fingolimod (Gilenya)ApprovedSmall moleculeSphingosine 1-phosphate receptor (S1PR, specifically S1P1), S1P receptor, Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)Reliable signal
NCT00289978: Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Fingolimod 1.25 mg 0.16 Relapses per year (95% CI 0.13 to 0.19) | Fingolimod 0.5 mg 0.18 Relapses per year (95% CI 0.15 to 0.22) vs Placebo 0.4 Relapses per year (95% CI 0.34 to 0.47)
NCT00340834: Annualized relapse rate over 12 months: fingolimod 1.25 mg 0.20 (95% CI 0.16 to 0.26) and 0.5 mg 0.16 (95% CI 0.12 to 0.21) vs interferon beta-1a IM 0.33 (95% CI 0.26 to 0.42); p<0.001 for both comparisons. n=1,292 randomized (TRANSFORMS, Cohen 2010, NEJM).
Interferon Beta-1a (Avonex)ApprovedBiologic (subtype unspecified)Type I Interferon receptor (IFNAR)Weak signal
NCT00211887: ARR - PDEs (Baseline to Month 36): IFN + GA 0.12 relapses per year | IFB-1a 0.16 relapses per year vs Glatiramer 0.11 relapses per year
Interferon Beta-1bApprovedBiologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptorPartial signal
NCT00185211: Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment): Initial IFNB-1b (Interferon Beta-1b) — Kaplan-Meier estimate at year 2: 26.9 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 36.7 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 46.2 cum. percentage of particip. with CDMS vs Initial Placebo — Kaplan-Meier estimate at year 2: 45 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 51.2 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 57.3 cum. percentage of particip. with CDMS
NCT00099502: Enrolled 897 (250mcg) + 899 (500mcg) + 448 (glatiramer acetate) = 2244 patients (matches this trial's enrollment). Annualized relapse rate 0.33-0.36 across arms; no statistically significant difference in relapse/progression measures between the 500mcg and 250mcg IFN beta-1b doses, or vs glatiramer acetate. missed
Natalizumab (Tysabri)ApprovedMonoclonal antibodyα4 integrinReliable signal
NCT00027300: Sustained disability progression at 2 years reduced 42% (hazard ratio 0.58, 95% CI 0.43-0.77, P<0.001; cumulative probability 17% natalizumab vs 29% placebo); clinical relapse rate at 1 year reduced 68% (P<0.001).
NCT03689972: Part 1: Mean Number of New or Newly Enlarging T2 Hyperintense Lesions at Week 72 (Week 72): Part 1: IV Q4W 0.05 number of T2 lesions (95% CI 0.01 to 0.22) | Part 1: IV Q6W 0.2 number of T2 lesions (95% CI 0.07 to 0.63)
OcrelizumabApprovedMonoclonal antibodyCD20Partial signal
NCT05123703: Protocol-defined annualized relapse rate: ocrelizumab 0.070 vs fingolimod 0.135; adjusted rate ratio 0.517 (95% CI 0.193 to 1.329), non-inferiority analysis (CT.gov posted results); Roche states non-inferiority to fingolimod with a 48% lower relapse risk.
NCT01247324: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks (Week 96): Interferon Beta-1a 44 mcg SC 0.292 relapses/participant year of treatment (95% CI 0.235 to 0.361) | Ocrelizumab 0.156 relapses/participant year of treatment (95% CI 0.122 to 0.2)
Ocrevus ZunovoApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
OfatumumabApprovedMonoclonal antibodyCD20Reliable signal
NCT02792231: Annualized Relapse Rate (ASCLEPIOS II): 0.10 (ofatumumab) vs 0.25 (teriflunomide); difference -0.15 (95% CI: -0.20, -0.09)
NCT02792218: Annualized relapse rate (median 1.6-year follow-up): 0.11 ofatumumab vs 0.22 teriflunomide; difference -0.11 (95% CI -0.16 to -0.06).
Ozanimod (Zeposia)ApprovedSmall moleculeS1P receptorPartial signal
NCT02047734: Adjusted annualized relapse rate (ARR) over 24 months (RADIANCE): 0.17 ozanimod 1.0mg, 0.22 ozanimod 0.5mg, vs 0.28 interferon beta-1a; rate ratio vs interferon 0.62 (p<0.0001) for the 1.0mg dose and 0.79 (p=0.0167) for the 0.5mg dose
NCT02294058: Adjusted Annualized Relapse Rate (ARR) During the Treatment Period (12 months): Ozanimod 0.5 mg 0.241 relapses/year (95% CI 0.188 to 0.308) | Ozanimod 1 mg 0.181 relapses/year (95% CI 0.14 to 0.236) vs Interferon Beta-1a 0.35 relapses/year (95% CI 0.279 to 0.44)
Peginterferon Beta-1a (Plegridy)ApprovedBiologic (subtype unspecified)Type I interferon receptor, Interferon beta receptor (type I IFN signaling)Reliable signal
NCT00906399: Annualized Relapse Rate (ARR) at 1 Year (1 Year): Year 1: Peginterferon Beta-1a Q4W 0.288 relapses per person-years (95% CI 0.234 to 0.355) | Year 1: Peginterferon Beta-1a Q2W 0.256 relapses per person-years (95% CI 0.206 to 0.318) vs Year 1: Placebo 0.397 relapses per person-years (95% CI 0.328 to 0.481)
NCT01939002: New or increased FLS during the first 8 weeks: 10.3% overall versus 25% null (p<0.0001); current FLS therapy 13% versus naproxen 7.4% (p=0.2037).
PonesimodApprovedSmall moleculeS1P receptorReliable signal
NCT02425644: Annualized relapse rate at week 108: 0.202 ponesimod vs 0.290 teriflunomide; rate ratio 0.695 (99% CI 0.536-0.902); 30.5% relative reduction; P<.001.
Rebif (interferon Beta 1a)ApprovedBiologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptorWeak signalFeatured results are non-efficacy only in this race
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)Weak signalFeatured results are non-efficacy only in this race
Siponimod (Mayzent)ApprovedSmall moleculeS1P receptorWeak signal
NCT01665144: EXPAND (n=1,651), primary endpoint 3-month confirmed disability progression on EDSS: 26.3% with siponimod vs 31.7% with placebo; HR 0.79 (95% CI 0.65 to 0.95), Cox model p=0.0134 (CT.gov posted results).
Tascenso ODTApprovedSmall moleculeS1P receptornot yet gradedNo reviewed efficacy summary in this indication
Teriflunomide HMR1726 (Aubagio)ApprovedSmall moleculeDihydroorotate dehydrogenase (DHODH)Reliable signal
NCT03122652: Time to first clinical demyelinating event: unadjusted HR 0.37 (95% CI 0.16-0.84; P=.02), adjusted HR 0.28 (95% CI 0.11-0.71; P=.007), teriflunomide vs placebo (63% unadjusted / 72% adjusted risk reduction)
NCT00751881: Annualized relapse rate (core period): placebo 0.501, teriflunomide 7 mg 0.389 (relative reduction 22.3%, p=0.0183), 14 mg 0.319 (relative reduction 36.3%, p=0.0001); step-down testing, 14 mg first (CT.gov posted results).
Tyruko (natalizumab-Sztn)ApprovedMonoclonal antibodyα4 integrinnot yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)ApprovedMonoclonal antibodyCD20Reliable signal
NCT03277248: Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.091 relapses per participant-years (95% CI 0.049 to 0.169) vs Teriflunomide + IV Placebo 0.178 relapses per participant-years (95% CI 0.109 to 0.291)
NCT03277261: Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.076 relapses per participant-years (95% CI 0.042 to 0.138) | Teriflunomide + IV Placebo 0.188 relapses per participant-years (95% CI 0.124 to 0.283)
ABP 692Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
BCD-281Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Bexobrutideg
Phase 3(overall)
Small moleculeBruton's tyrosine kinase (BTK)
not yet graded(overall)
No reviewed efficacy summary in this indication
CT-P53Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Divozilimab (Ivlizi)Phase 3Monoclonal antibodyCD20Reliable signal
NCT05385744: Annualised relapse rate over 2 years (100 weeks): divozilimab 0.057 vs teriflunomide 0.164
FenebrutinibPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
FrexalimabPhase 3Monoclonal antibodyCD40 ligand (CD40L / CD154)not yet gradedNo reviewed efficacy summary in this indication
Nabiximols (Sativex)Phase 3BotanicalCannabinoid CB1/CB2 receptors (agonist)Partial signal
NCT04657666: Change From Baseline in Lower Limb Muscle Tone-6 (LLMT-6) (Baseline (predose Day 1 of Treatment Period 1) up to Day 51 (end of treatment of Treatment Period 2)): Nabiximols -0.23 units on a scale (Standard Error 0.07) vs Placebo -0.26 units on a scale (Standard Error 0.07) missed
NCT01610700: Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at the End of 6 Weeks of Treatment (baseline and 6 weeks): GW-1000-02 -25.32 units on a scale (Standard Deviation 23.42) vs Placebo -19.32 units on a scale (Standard Deviation 27.02) missed
TolebrutinibPhase 3Small moleculeBruton's tyrosine kinase (BTK)Reliable signal
NCT04411641: HERCULES (n=1,131, nrSPMS), primary endpoint time to onset of 6-month confirmed disability progression on EDSS: tolebrutinib 60 mg vs placebo HR 0.693 (95% CI 0.546 to 0.880), Cox regression p=0.0026 (CT.gov posted results).
NCT04458051: 6-month composite confirmed disability progression (cCDP), tolebrutinib vs placebo: HR 1.01 (95% CI 0.81-1.26), p=.94 — no difference from placebo. missed
Vidofludimus CalciumPhase 3—Dihydroorotate dehydrogenase (DHODH)not yet gradedNo reviewed efficacy summary in this indication
CNM-Au8Phase 2/3Nanoparticlemitochondrial energy metabolismPartial signal
NCT04626921: LCLA (Best-Corrected Low-Contrast Letter Acuity) change across both eyes at Week 144 vs original randomization baseline, CNM-Au8 arm: least-squares mean difference +8.70 letters (SE 1.88), 95% CI 5.0 to 12.4, p<0.0001
CorubrutinibPhase 2Small moleculeBruton's tyrosine kinase (BTK)Partial signal
NCT05798520: Biogen reported that BIIB091 achieved proof-of-concept in relapsing-remitting MS (no figures released)
ForalumabPhase 2Monoclonal antibodyCD3not yet gradedNo reviewed efficacy summary in this indication
IrafamdastatPhase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
A-005
Phase 1(overall)
Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
AZD0120Phase 1Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
Azercabtagene Zapreleucel
Phase 1(overall)
Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
IDP-023Phase 1Cell therapyAllogeneic g-NK cell therapynot yet gradedNo reviewed efficacy summary in this indication
RG6035
—(overall)
Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
RG6182
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
BaminerceptDiscontinuedProtein / enzyme therapeuticLymphotoxin-beta receptor (LTβR)not yet gradedNo reviewed efficacy summary in this indication
Firategrast (SB-683699)DiscontinuedSmall moleculeVLA-4 (integrin alpha-4/beta-1), Integrin alpha-4 (ITGA4)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(16 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow remibrutinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (6)
February 2027 (1)
Phase 3Chronic Spontaneous UrticariaActive not recruiting
Est. primary completion 2027-02-22 · NCT06868212 · CT.gov ↗
What to watch
May 2027 (1)
Phase 3Hidradenitis SuppurativaActive not recruiting
Est. primary completion 2027-05-17 · NCT06799000 · CT.gov ↗
What to watch
June 2027 (1)
Phase 3Hidradenitis SuppurativaActive not recruiting
Est. primary completion 2027-06-03 · NCT06840392 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Chronic Spontaneous UrticariaRecruiting
Est. primary completion 2027-08-23 · NCT06865651 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1Hidradenitis SuppurativaRecruiting
Est. primary completion 2027-11-29 · NCT07855276 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Papulopustular RosaceaRecruiting
Est. primary completion 2027-12-07 · NCT07681271 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
Phase 3Generalized Myasthenia GravisActive not recruitingDiscontinued in this indication
Est. primary completion 2028-02-25 · NCT06744920 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Chronic Spontaneous UrticariaRecruiting
Est. primary completion 2028-05-24 · NCT07816328 · CT.gov ↗
What to watch
2029 (4)
February 2029 (1)
Phase 3Chronic Pruritus of Unknown OriginRecruiting
Est. primary completion 2029-02-26 · NCT07811869 · CT.gov ↗
What to watch
March 2029 (1)
Phase 3IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg AllergyRecruiting
Est. primary completion 2029-03-30 · NCT07768371 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Multiple SclerosisRecruiting
Est. primary completion 2029-07-25 · NCT06846281 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Chronic Pruritus of Unknown OriginRecruiting
Est. primary completion 2029-12-19 · NCT07700056 · CT.gov ↗
What to watch
2030 (2)
October 2030 (1)
Phase 2Multiple SclerosisNot yet recruiting
Est. primary completion 2030-10-30 · NCT07222956 · CT.gov ↗
What to watch
December 2030 (1)
Phase 3Multiple SclerosisRecruiting
Est. primary completion 2030-12-03 · NCT07225504 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Phase 3Hidradenitis SuppurativaRecruiting
Est. primary completion 2031-10-15 · NCT07665437 · CT.gov ↗
What to watch
2033 (1)
January 2033 (1)
Phase 3Indication of the Parent ProtocolRecruiting
Est. primary completion 2033-01-30 · NCT07456891 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

October 2026ApprovalFDA approves Rhapsido for symptomatic dermographism
US, FDA · Novartis · Source ↗
1 September 2026Topline resultNovartis reports the Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing MS met their primary endpoint
Novartis · Source ↗
18 February 2026Topline resultPositive topline results from Phase III RemIND trial in CIndU
18 February 2026Filing submittedsNDA submitted to FDA for symptomatic dermographism
US, FDA · Source ↗